Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.52 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.52 |
| ▸ | ME2 | P23368 | 5/20 | 0.46 |
| ▸ | ME1 | P48163 | 5/20 | 0.46 |
| ▸ | ME3 | Q16798 | 5/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 9/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1735467 | 0.99 | CYP19A1 (0.53) | CYP19A1AOC3ME2ME1ME3 | |
| SCHEMBL1732997 | 0.88 | AOC3 (0.54) | CYP19A1AOC3ME2ME1ME3 | |
| SCHEMBL4951237 | 0.76 | CYP19A1 (0.61) | CYP19A1 | |
| SCHEMBL3684699 | 0.73 | AOC3 (0.54) | AOC3ME2ME1ME3 | |
| SCHEMBL1734187 | 0.73 | CYP19A1 (0.57) | CYP19A1 | |
| SCHEMBL1841587 | 0.70 | CYP19A1 (1.00) | CYP19A1 | |
| SCHEMBL987818 | 0.70 | AOC3 (0.55) | AOC3CNR2 | |
| SCHEMBL3216381 | 0.70 | CYP19A1 (0.60) | CYP19A1 | |
| Dihydrochalcone SCHEMBL29359372 | 0.70 | CYP19A1 (0.80) | CYP19A1ABCB1 | |
| Dihydrochalcone SCHEMBL2827303 | 0.70 | CYP19A1 (0.80) | CYP19A1ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8715761-B2 | Flavor molecules | GIVAUDAN S.A. (CH) | 2014-05-06 | — | — | US | disclosed |
| US-20130281387-A1 | Chemosensory Receptor Ligand-Based Therapies | ELCELYX THERAPEUTICS, INC. (US) | 2013-10-24 | — | — | US | disclosed |
| US-20130281387-A1 | Chemosensory Receptor Ligand-Based Therapies | ELCELYX THERAPEUTICS, INC. (US) | 2013-10-24 | — | — | US | disclosed |
| US-8449936-B2 | Flavor molecules | GIVAUDAN SA (CH) | 2013-05-28 | — | — | US | disclosed |
| WO-2012054528-A2 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | ELCELYX THERAPEUTICS, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
| EP-2259689-B1 | FLAVOR MOLECULES | GIVAUDAN SA (CH) | 2011-11-16 | — | — | EP | disclosed |
| US-20100272656-A1 | Flavor Molecules | GIVAUDAN SA (CH) | 2010-10-28 | — | — | US | disclosed |
| US-20100040753-A1 | FLAVOR MOLECULES | GIVAUDAN SA (CH) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100272656-A1 | Flavor Molecules | TAS2R30, TAS2R31, TAS2R1 | CYP19A1 3585/4885AOC3 402/4885ME2 1454/4885 |
| US-20100040753-A1 | FLAVOR MOLECULES | TAS2R30, TAS2R31, TAS2R1 | CYP19A1 3585/4885AOC3 402/4885ME2 1454/4885 |
| US-20130281387-A1 | Chemosensory Receptor Ligand-Based Therapies | GPR119, TAS1R2, TAS2R1 | CYP19A1 2441/4885AOC3 2554/4885ME2 1790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.